Experimental study of the pharmacokinetics of monoclonal antibodies to α4β1-integrin in guinea pigs
Abstract
This article presents the data on pharmacodynamics evaluation of monoclonal antibodies to α4β1-integrin in guinea pigs. The effect on total content of peripheral blood leukocytes after a single intraperitoneal injection of three doses of the drug has been studied. It was shown that intraperitoneal injection of the drug at doses of 30, 60, and 120 mg/kg causes a twofold increase in the content of leukocytes in the first hours after the administration, reaching a maximum value to 6th day. Subsequently 11-18 days, depending on dose, leukocytes content gradually decreased to control values.
About the Authors
B. N. Krapivin
CJSC «BIOCAD»
Russian Federation
Senior researcher of the Department of preclinical trials of drug products
Russian Federation
Senior researcher of the Department of preclinical trials of drug products
O. V. Goncharova
CJSC «BIOCAD»
Russian Federation
Head of the Department of recombinant proteins. Candidate of Biological Sciences
Russian Federation
Head of the Department of recombinant proteins. Candidate of Biological Sciences
E. L. Morozova
CJSC «BIOCAD»
Russian Federation
Head of the Department of preclinical trials of drug products
Russian Federation
Head of the Department of preclinical trials of drug products
References
1. Mumentaler Ì, Mattle H. Neurology. 3rd ed. Moscow: MEDpress-Inform; 2011 (in Russian).
2. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol. 2007; 6(10): 903–12.
3. Goodin DS, Cohen BA, O’Connor P, et al. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 71: 766–73.
4. Lobb RR, Hemler ME. The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest. 1994; 94: 1722–8.
5. Brocke S, Piercy C, Steinman L, et al. Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc Natl Acad Sci USA 1999; 96: 6896–901.
6. Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005; 64: 1336–42.
7. Ley K, Laudanna C, Cybulsky MI, et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007; (7): 678–89.
8. Wehner NG, Gasper C, Shopp G, Nelson J, Draper K, Parker S, Clarke J. Immunotoxicity profile of natalizumab. J Immunotoxicol. 2009; 6(2): 115–29.
9. Truhacheva NV. Mathematical Statistics in biomedical research with Statistica package. Moscow: GEOTAR-Media; 2013 (in Russian).
Review
For citations:
Krapivin B.N., Goncharova O.V., Morozova E.L. Experimental study of the pharmacokinetics of monoclonal antibodies to α4β1-integrin in guinea pigs. BIOpreparations. Prevention, Diagnosis, Treatment. 2016;16(3):179-181. (In Russ.)
Views:
588
Email this article 